Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma announced the completion of dosing for the last patient in their Phase 2/3 LIFT-AD clinical trial of fosgonimeton, aimed at treating mild-to-moderate Alzheimer's disease (AD). The trial involved approximately 315 patients, assessing the efficacy and safety of fosgonimeton through once-daily subcutaneous injections over a 26-week period. Athira plans to release topline results by the end of Q3 2024 and will present detailed data at the CTAD conference on October 29, 2024, in Madrid. The primary endpoint, the GST, evaluates changes in cognition and function using the ADAS-Cog11 and ADCS-ADL23 tests. The trial also includes serum biomarker analysis to explore the neuroprotective effects of fosgonimeton. Additionally, a significant portion of participants have enrolled in an open-label extension study, with over 70 patients continuing treatment beyond 18 months.
Athira Pharma will host a webinar on June 18, 2024, to discuss the potential of fosgonimeton for treating mild-to-moderate Alzheimer's disease (AD). The event will cover the ongoing Phase 2/3 LIFT-AD trial, with topline data expected in the second half of 2024. Chief Medical Officer Javier San Martin, alongside two neurodegeneration experts, will review the trial's primary endpoint, the Global Statistical Test (GST), which measures cognition and function. The webinar will provide insights into the unmet medical needs in AD and the potential benefits of fosgonimeton.
Athira Pharma has completed the first cohort in its Phase 1 clinical trial for ATH-1105, a potential treatment for ALS. This first-in-human, dose-escalation study aims to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. The trial is expected to conclude by the end of 2024, with a Phase 2 study in ALS patients slated for 2025. Preclinical data indicates that ATH-1105 can improve motor function, preserve nerve health, and extend survival in ALS models. The Phase 1 trial will involve up to 80 healthy participants and will evaluate single and multiple ascending doses of the drug.
Athira Pharma (NASDAQ: ATHA), a late-stage clinical biopharmaceutical company, announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Healthcare Conference on June 5 and the Goldman Sachs 45th Annual Healthcare Conference on June 12. These events will feature fireside chats where Athira’s management will discuss the company’s robust pipeline focused on neurodegenerative diseases. They will also highlight the progress of the LIFT-AD Phase 2/3 trial in Alzheimer’s Disease, with topline data expected in the second half of 2024. The fireside chats will be webcast live on Athira's Investor Relations website, with replays available for 30 days post-event.
Athira Pharma (NASDAQ: ATHA) announced a proposed settlement for stockholder derivative actions. The settlement, preliminarily approved by the U.S. District Court for the Western District of Washington, involves adopting corporate governance reforms and paying legal fees and service awards to lead plaintiffs. A final approval hearing is scheduled for July 18, 2024. Relevant documents have been posted on Athira's Investor Relations website.
Athira Pharma (NASDAQ: ATHA) released its Q1 2024 financial results and highlighted pipeline and business updates. The company is anticipating topline data from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for Alzheimer's disease in H2 2024. They've also filed an IND application for ATH-1105 for ALS treatment and plan a first-in-human study in Q2 2024. Financially, Athira reported a net loss of $26.3 million, or $0.69 per share, compared to $27.8 million, or $0.73 per share, in Q1 2023. Cash reserves stand at $122.1 million, down from $147.4 million in December 2023. R&D expenses were $21.2 million, while G&A expenses dropped to $6.5 million. The company remains focused on advancing its small molecule drug candidates targeting the HGF system to treat neurodegenerative diseases.
Summary: Athira Pharma, Inc. (NASDAQ: ATHA) will be participating in the Sidoti May 2024 Virtual Investor Conference and The Citizens JMP Life Sciences Conference in May. The Company management will present at these conferences to discuss their focus on developing small molecules to restore neuronal health and slow neurodegeneration. Live webcasts and archived replays will be available on the Athira website.
FAQ
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
